Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
Daiichi Sankyo
Boehringer Ingelheim
Cerilliant
Accenture
Chinese Patent Office
McKesson
Teva

Generated: November 13, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021814

« Back to Dashboard

NDA 021814 describes APTIVUS, which is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the APTIVUS profile page.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.
Summary for 021814
Tradename:APTIVUS
Applicant:Boehringer Ingelheim
Ingredient:tipranavir
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 021814
Generic Entry Date for 021814*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 021814
Mechanism of ActionHIV Protease Inhibitors
Suppliers and Packaging for NDA: 021814
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
APTIVUS tipranavir CAPSULE;ORAL 021814 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0003 0597-0003-02 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (0597-0003-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength250MG
Approval Date:Jun 22, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 22, 2019Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Apr 29, 2020Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Jan 27, 2019Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKesson
Fish and Richardson
Accenture
Citi
Cipla
Cerilliant
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.